On November 25, 2019 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, reported management’s participation in the following investor and scientific conferences in December (Press release, Immunic, NOV 25, 2019, View Source [SID1234551676]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

December 3-5: Piper Jaffray 31st Annual Healthcare Conference: Sanjay Patel, CFA, Chief Financial Officer of Immunic, will present a company overview at the Piper Jaffray 31st Annual Healthcare Conference in New York on Thursday, December 5, at 12:10 pm EST.
December 4: Crohn’s and Colitis Foundation IBD Innovate Conference: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present, for the first time, data on IMU-856 at the Crohn’s and Colitis Foundation IBD Innovate Conference in New York on Wednesday, December 4. The presentation, entitled, "IMU-856: A Small Molecule Modulator Restoring the Gut Barrier Function," will be given as part of the Small & Large Molecules session beginning at 11:40 am EST.